Holen Sie sich die Stockscreener-App
2.275
1.73%
-0.035
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.31
Offen:
$2.29
24-Stunden-Volumen:
4.91M
Relative Volume:
0.37
Marktkapitalisierung:
$901.12M
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-1.8496
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
+6.32%
1M Leistung:
-1.30%
6M Leistung:
+2.71%
1J Leistung:
-74.61%
1-Tages-Spanne:
$2.24
$2.325
1-Wochen-Bereich:
$2.14
$2.34
52-Wochen-Spanne:
$1.6385
$8.90
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.27 | 917.00M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Globe and Mail
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
How buyback programs support Iovance Biotherapeutics Inc. (2LB) stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock is upgraded to buyMarket Activity Recap & Daily Technical Forecast Reports - Newser
What dividend safety rating applies to Iovance Biotherapeutics Inc. (2LB) stock2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsChart Signals & Community Trade Idea Sharing Platform - Newser
Is Iovance Biotherapeutics Inc. (2LB) stock ideal for retirement investors2025 Fundamental Recap & Precise Trade Entry Recommendations - Newser
Why Iovance Biotherapeutics Inc. stock remains undervaluedJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9%What's Next? - MarketBeat
FINAL REMINDER IOVA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA)Join by July 14, 2025Contact Levi & Korsinsky - The National Law Review
Iovance Biotherapeutics Stock Dips Amid Market Reactions - StocksToTrade
Virtus Investment Advisers LLC Increases Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc - The National Law Review
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi - The National Law Review
Kennondale Capital Management LLC Invests $384,000 in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Iovance’s Tumultuous Journey: Positive Drug Trials Amidst Financial Turbulence - StocksToTrade
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA) - Seeking Alpha
Barclays Boosts IOVA Price Target to $9, Maintains Overweight Ra - GuruFocus
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
Iovance (NASDAQ: IOVA) grants inducement stock options on 164,900 shares at $2.18 - Stock Titan
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Strategies to average down on Iovance Biotherapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
Can Iovance Biotherapeutics Inc. stock deliver sustainable ROEJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Why Iovance Biotherapeutics Inc. stock appeals to analystsJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Is Iovance Biotherapeutics Inc. (2LB) stock overpriced at current multiplesJuly 2025 Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):